Airbnb, Inc. vs ResMed Inc. — how do they compare? Airbnb, Inc. trades at $180.35 (market cap $110.76B), while ResMed Inc. trades at $224.14 (market cap $32.61B). The key difference: Airbnb, Inc. is far larger — about 3.4× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while Airbnb, Inc. pays none. Which is the better fit depends on your goals.
| ABNB | RMD | |
|---|---|---|
Market Cap | $110.76B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $293.73 |
52-Week Low | $111.54 | $182.82 |
Enterprise Value | $101.19B | $31.97B |
Dividend Yield | — | 1.17% |
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $184.70, up 3.72% in 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving averages and recent earnings beat in Q2 2026. Revenue growth is steady, with 2025 revenue at $12.24 billion and net income of $2.51 billion, though Q4 2025 and Q1 2026 EPS missed expectations. Analyst sentiment is mixed with a consensus price target of $173.26, below the current price, and news highlights AI-driven growth initiatives.
Outlook is cautiously optimistic with AI expansion boosting bookings and margins, but high valuation ratios like a P/E of 42.23 pose risks. Competition and economic sensitivity are key concerns. Institutional holdings and bullish technical trends support upside potential if execution continues.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Trailing returns across standard periods
Latest headlines on both assets
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →